The vice president and Asset Head of Rare and Ultra-Rare Diseases at UCB discussed the landmark FDA approval of doxecitine/doxribitine, the first-ever therapy for thymidine kinase 2 deficiency (TK2d). [WATCH TIME: 3 minutes]
Fabian Somers, PhD
Advertisement
Articles by Fabian Somers, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Action Update, October 2025: Clearance, Acceptance, and Extension
2
OnabotulinumtoxinA Fails to Meet Primary End Point in Phase 3 PRECLUDE Trial for Episodic Migraine
3
FDA Clears Phase 2a Clinical Trial to Test JOTROL in Patients With Parkinson Disease
4
Caregiver Decision-Making for Duchenne Gene Therapy Use Requires Collaborative Input, Thoughtful Consideration
5
